3,3'-Dihydroxystilben | 70709-65-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3,3'-Dihydroxystilben
• 英文别名: 3,3'-(1,2-Ethenediyl)bisphenol；3-[2-(3-hydroxyphenyl)ethenyl]phenol
• CAS: 70709-65-8
• 化学式: C₁₄H₁₂O₂
• 分子量: 212.248
• InChiKey: VLOHFQFIKQIMBT-UHFFFAOYSA-N

物化性质

• 沸点：
  427.9±34.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,3'-Dihydroxystilben 在 palladium on activated charcoal 作用下， 以 乙醇 为溶剂， 生成 3,3'-(ethane-1,2-diyl)diphenol
  参考文献：
  名称：

  A Bisphenolic Honokiol Analog Outcompetes Oral Antimicrobial Agent Cetylpyridinium Chloride via a Membrane-Associated Mechanism

  摘要：

  Targeting Streptococcus mutans is the primary focus in reducing dental caries, one of the most common maladies in the world. Previously, our groups discovered a potent bactericidal biaryl compound that was inspired by the natural product honokiol. Herein, a structure activity relationship (SAR) study to ascertain structural motifs key to inhibition is outlined. Furthermore, mechanism studies show that bacterial membrane disruption is central to the bacterial growth inhibition. During this process, it was discovered that analog C2 demonstrated a 4-fold better therapeutic index compared to the commercially available antimicrobial cetylpyridinium chloride (CPC) making it a viable alternative for oral care.

  DOI：

  10.1021/acsinfecdis.9b00190
• 作为产物：
  描述：

  3-羟基苯乙酸 在 copper chromite 喹啉 、 乙酸酐 、 三乙胺 作用下， 生成 3,3'-Dihydroxystilben
  参考文献：
  名称：

  Hata,K. et al., Chemical and pharmaceutical bulletin, 1979, vol. 27, p. 984 - 989

  摘要：

  DOI：

文献信息

• Anti-proliferative composition
  申请人：Nutricia N.V.

  公开号：EP1314438A1

  公开（公告）日：2003-05-28

  Non-estrogen-dependent hyperproliferation of cells in animals or humans can be prevented or treated by means of a pharmaceutical or nutritional composition containing a combination of a) two or more inhibitors of the G1/S phase of the cell cycle; and b) two or more inhibitors of the G2/M phase of the cell cycle; and c) two or more inhibitors of protein tyrosine kinase activity. Especially, component a) comprises two or more compounds selected from flavanolignans, carotenoids and isoflavone; component b) comprises two or more compounds selected from flavanolignans, hydroxylated stilbenes, isoflavones and apigenin; and component c) comprises two or more compounds selected from flavanolignans and isoflavones.

  动物或人体内非雌激素依赖性细胞过度增殖可通过含有以下成分组合的药物或营养组合物来预防或治疗 a) 细胞周期 G1/S 期的两种或两种以上抑制剂；以及 b) 细胞周期 G2/M 期的两种或两种以上抑制剂；以及 c) 两种或两种以上蛋白酪氨酸激酶活性抑制剂。 特别是，成分 a) 包括两种或两种以上选自黄烷木质素、类胡萝卜素和异黄酮的化合物；成分 b) 包括两种或两种以上选自黄烷木质素、羟基化芪、异黄酮和芹菜素的化合物；成分 c) 包括两种或两种以上选自黄烷木质素和异黄酮的化合物。
• Low melting and low viscosity thermoset matrix resins from the Z configuration of polyhydroxy stilbenes
  申请人：The United States of America, as represented by the Secretary of the Navy

  公开号：US10723834B1

  公开（公告）日：2020-07-28

  The invention generally relates to novel poly-substituted cis stilbenes, their synthesis, their purification, and their use in thermoset resins. These novel cis stilbenes give rise to thermoset resins with greatly improved processing characteristics such as lower melting temperature and lower viscosity; resulting in polymers and composites having greatly improved thermal stability.

  本发明一般涉及新型多取代顺式二苯乙烯、其合成、纯化及其在热固性树脂中的应用。这些新型顺式二苯乙烯可产生热固性树脂，大大改善其加工特性，如降低熔化温度和粘度，从而使聚合物和复合材料的热稳定性大大提高。
• Ionic‐Liquid‐Influenced Expeditious and Stereoselective Synthesis of Olefins
  作者：Sachin V. Bhilare、Nitin B. Darvatkar、Amol R. Deorukhkar、Meghana S. Rasalkar、Manikrao M. Salunkhe

  DOI：10.1080/00397910701544794

  日期：2007.9.1

  1-Butyl-3-methylimidazolium chloroaluminate, [bmim] Cl center dot. AlCl3 (molar fraction, N = 0.67), ionic liquid has been used in combination with metallic Zn for the reductive coupling of carbonyl compounds to synthesize symmetrical olefins, with the Z-isomer formed predominantly. The ionic liquid played a dual role of Lewis acid catalyst and solvent.
• ANTI-PROLIFERATIVE COMPOSITION
  申请人：N.V. Nutricia

  公开号：EP1448232A1

  公开（公告）日：2004-08-25
• KINASE INHIBITOR COMPOUNDS
  申请人：University of Florida Research Foundation, Inc.

  公开号：EP2376425A2

  公开（公告）日：2011-10-19